- Conditions
- Recessive Dystrophic Epidermolysis Bullosa
- Interventions
- Rigosertib Sodium, Quality-of-Life Assessment
- Drug · Other
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 54
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Epidermolysis Bullosa Dystrophica
- Interventions
- Not listed
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa Dystrophica, Recessive, Epidermolysis Bullosa Dystrophica Dominans
- Interventions
- Not listed
- Lead sponsor
- Krystal Biotech, Inc.
- Industry
- Eligibility
- 6 Months and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Recessive Dystrophic Epidermolysis Bullosa
- Interventions
- Gentamicin
- Drug
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 7 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Epidermolysis Bullosa, Dystrophic, Epidermolysis Bullosa, Junctional
- Interventions
- Filsuvez
- Drug
- Lead sponsor
- Chiesi Farmaceutici S.p.A.
- Industry
- Eligibility
- Not listed
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 6
- States / cities
- Palo Alto, California • Aurora, Colorado • Gainesville, Florida + 3 more
- Conditions
- Epidermolysis Bullosa Dystrophica, Recessive, Epidermolysis Bullosa Dystrophica, Dominant
- Interventions
- QR-313, Placebo
- Drug
- Lead sponsor
- Phoenicis Therapeutics
- Industry
- Eligibility
- 4 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 4
- States / cities
- Palo Alto, California • Aurora, Colorado • Minneapolis, Minnesota + 1 more
- Conditions
- Epidermolysis Bullosa
- Interventions
- SD-101 dermal cream (3%), SD-101 Dermal Cream (6%), Vehicle (SD-101 0%)
- Drug
- Lead sponsor
- Scioderm, Inc.
- Industry
- Eligibility
- 6 Months and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 7
- States / cities
- Palo Alto, California • Chicago, Illinois • St Louis, Missouri + 4 more
- Conditions
- Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa
- Interventions
- Open Label Topical Beremagene Geperpavec (B-VEC)
- Biological
- Lead sponsor
- Krystal Biotech, Inc.
- Industry
- Eligibility
- 2 Months and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 6
- States / cities
- Rancho Santa Margarita, California • Redwood City, California • Coral Gables, Florida + 3 more
- Conditions
- Epidermolysis Bullosa
- Interventions
- busulfan, cyclophosphamide, fludarabine phosphate, hematopoietic bone marrow transplantation
- Drug · Procedure
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 25 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa
- Interventions
- Not listed
- Lead sponsor
- Krystal Biotech, Inc.
- Industry
- Eligibility
- 6 Months and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 3
- States / cities
- Rancho Santa Margarita, California • Redwood City, California • Coral Gables, Florida
- Conditions
- Epidermolysis Bullosa (EB), Epidermolysis Bullosa Simplex, Dystrophic Epidermolysis Bullosa, Junctional Epidermolysis Bullosa
- Interventions
- Diacerein 1% Ointment
- Drug
- Lead sponsor
- Castle Creek Pharmaceuticals, LLC
- Industry
- Eligibility
- 4 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 3
- States / cities
- Palo Alto, California • Chicago, Illinois • Chapel Hill, North Carolina
- Conditions
- RDEB
- Interventions
- EB-101
- Biological
- Lead sponsor
- Abeona Therapeutics, Inc
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2036
- U.S. locations
- 2
- States / cities
- Redwood City, California • Worcester, Massachusetts
- Conditions
- Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa
- Interventions
- EB-101
- Biological
- Lead sponsor
- Abeona Therapeutics, Inc
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 2
- States / cities
- Redwood City, California • Worcester, Massachusetts
- Conditions
- Dystrophic Epidermolysis Bullosa, Junctional Epidermolysis Bullosa
- Interventions
- Filsuvez topical gel: 10% birch triterpenes
- Drug
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 0 Days to 5 Months
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2029
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Recessive Dystrophic Epidermolysis Bullosa
- Interventions
- PTR-01, Normal saline
- Drug
- Lead sponsor
- Phoenix Tissue Repair, Inc.
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 3
- States / cities
- Redwood City, California • Aurora, Colorado • Philadelphia, Pennsylvania
- Conditions
- Recessive Dystrophic Epidermolysis Bullosa
- Interventions
- allo-APZ2-EB
- Biological
- Lead sponsor
- RHEACELL GmbH & Co. KG
- Industry
- Eligibility
- 0 Years to 55 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Recessive Dystrophic Epidermolysis Bullosa
- Interventions
- PTR-01
- Drug
- Lead sponsor
- Phoenix Tissue Repair, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 2
- States / cities
- Redwood City, California • Aurora, Colorado
- Conditions
- Dystrophic Epidermolysis Bullosa
- Interventions
- Topical beremagene geperpavec, Placebo gel
- Biological
- Lead sponsor
- Krystal Biotech, Inc.
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Epidermolysis Bullosa
- Interventions
- SD-101-6.0 cream
- Drug
- Lead sponsor
- Scioderm, Inc.
- Industry
- Eligibility
- 1 Month and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Redwood City, California • Aurora, Colorado + 12 more
- Conditions
- Epidermolysis Bullosa Dystrophica
- Interventions
- Not listed
- Lead sponsor
- Stanford University
- Other
- Eligibility
- Not listed
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2029
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Dystrophic Epidermolysis Bullosa
- Interventions
- Not listed
- Lead sponsor
- Lotus Tissue Repair, Inc.
- Industry
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Junctional Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa
- Interventions
- RGN-137, Placebo
- Drug
- Lead sponsor
- Lenus Therapeutics, LLC
- Industry
- Eligibility
- 4 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 5
- States / cities
- Evanston, Illinois • Brooklyn, New York • Cincinnati, Ohio + 2 more
- Conditions
- Epidermolysis Bullosa
- Interventions
- Survey
- Other
- Lead sponsor
- Amicus Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Cranbury, New Jersey
- Conditions
- Epidermolysis Bullosa
- Interventions
- SD-101 dermal cream (6%)
- Drug
- Lead sponsor
- Scioderm, Inc.
- Industry
- Eligibility
- 6 Months and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 7
- States / cities
- Palo Alto, California • Chicago, Illinois • St Louis, Missouri + 4 more